LEEOMIC: CompLEEment-1 Canadian Correlative Sub-Study Comprehensive Proteomic Analysis Towards Discovery of Predictive Patterns of Protein Expression to Ribociclib Sensitivity and Resistance
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms LEEomic
- Sponsors Novartis Pharmaceuticals
- 31 Jan 2019 Planned End Date changed from 28 Dec 2018 to 3 Apr 2019.
- 31 Jan 2019 Planned primary completion date changed from 28 Dec 2018 to 2 Apr 2019.
- 31 Jan 2019 Planned initiation date changed from 30 Oct 2018 to 1 Apr 2019.